Momenta Phama (MNTA) – StreetInsider.com Reports
-
Johnson & Johnson (JNJ) Completes Acquisition of Momenta Pharmaceuticals, Inc. (MNTA)
-
Pre-Open Stock Movers 09/28: (PLL) (PRCP) (GNFT) Higher; (INO) (AQST) (VIPS) Lower (more...)
-
Chesapeake Utilities (CPK) to Join S&P SmallCap 600
-
Momenta Phama (MNTA) Announces Expiration of Hart-Scott-Rodino Waiting Period in Connection with Proposed Sale to Johnson & Johnson (JNJ)
-
H.C. Wainwright Downgrades Momenta Pharmaceuticals (MNTA) to Neutral
-
Raymond James Starts Momenta Pharmaceuticals (MNTA) at Market Perform
-
Johnson & Johnson (JNJ) Sees Nipocalimab as Underappreciated with >$1B in Peak Sales - Credit Suisse
-
Stifel Downgrades Momenta Pharmaceuticals (MNTA) to Hold
-
JPMorgan Downgrades Momenta Pharmaceuticals (MNTA) to Neutral, Following Acquisition
-
Pre-Open Stock Movers 08/19: (MNTA) (HUD) (IMVT) Higher; (BMRN) (GLPG) (VIPS) Lower (more...)
-
Wells Fargo Downgrades Momenta Pharmaceuticals (MNTA) to Equal Weight
-
Momenta Phama (MNTA) IV at 106 into Johnson & Johnson (JNJ) acquiring for $6.5B
-
J&J/Momenta Deal Positive for argenx (ARGX), Immunovant (IMVT) - Guggenheim
-
Immunovant (IMVT) Has Positive 'Read-Through' from JNJ/MNTA Deal - Truist Securities
-
Johnson & Johnson (JNJ) May Have Underpaid for Momenta Phama (MNTA), Sees Fair Value of $74/Share
-
Immunovant (IMVT), argenx (AGRX) Gain as J&J Acquires Momenta
-
Momenta Phama (MNTA) Confirms Definitive Agreement to be Acquired by Johnson & Johnson (JNJ) $52.50/sh
-
Johnson & Johnson (JNJ) to Acquire Momenta Pharmaceuticals Inc. (MNTA) for $52.50/Share
-
Momenta Phama (MNTA) Defended By Stifel, Buy On Weakness
-
Momenta Phama (MNTA) Misses Q2 EPS by 9c, Revenues Beat
-
UPDATE: Cowen Transfers, Upgrades Momenta Pharmaceuticals (MNTA) to Outperform
-
Momenta Pharmaceuticals (MNTA) Well Positioned Ahead of M254 Phase I/II Part B Update - Piper Sandler
-
Momenta Pharmaceuticals (MNTA) PT Raised to $50 at H.C. Wainwright
-
Momenta Phama (MNTA) Granted FDA Rare Pediatric Disease Designation for Nipocalimab in HDFN
-
Momenta Pharmaceuticals (MNTA) PT Raised to $57 at SunTrust
-
Momenta Pharmaceuticals (MNTA) PT Raised to $36 at Goldman Sachs
-
Momenta Pharmaceuticals (MNTA) PT Raised to $36 at Goldman Sachs, Following Trial Data Release Yesterday
-
Momenta Pharmaceuticals (MNTA) PT Raised to $40 at Cowen
-
Momenta Pharmaceuticals (MNTA) PT Raised to $46 at H.C. Wainwright
-
Momenta Pharmaceuticals (MNTA) PT Raised to $47 at Stifel
-
Momenta Phama (MNTA) Announces Positive Topline Data from Interim Analysis of Phase 2 Vivacity-MG Study of Nipocalimab in Generalized Myasthenia Gravis
-
Momenta Phama (MNTA) Tops Q1 EPS by 14c, Revenues Beat
-
Momenta Phama (MNTA) Provides Corporate Update Amid COVID-19 Pandemic
-
Goldman Sachs Starts Momenta Pharmaceuticals (MNTA) at Neutral
-
Momenta Pharmaceuticals (MNTA) PT Raised to $46 at Stifel, Following Earnings
-
Momenta Pharmaceuticals (MNTA) PT Raised to $30 at Cantor Fitzgerald
-
Momenta Phama (MNTA) Misses Q4 EPS by 29c, Revenues Beat
-
Momenta Pharmaceuticals (MNTA) PT Raised to $45 at Piper Sandler
-
Momenta Pharmaceuticals (MNTA) PT Raised to $43 at Stifel
-
Momenta Pharmaceuticals (MNTA) PT Raised to $43 at Stifel
-
Pre-Open Movers 01/15: (FLNT) (CLVS) (MNTA) Higher; (NKTR) (TGT) (FSLR) Lower (more...)
-
Momenta Pharmaceuticals (MNTA) PT Nearly Doubled to $50 at SunTrust on Data
-
After-Hours Stock Movers 01/14: (FLNT) (SRNE) (AESE) Higher; (NKTR) (BBCP) Lower (more...)
-
JPMorgan Upgrades Momenta Pharmaceuticals (MNTA) to Overweight
-
Momenta Phama (MNTA) Announces Year-End 2019 Update and 2020 Outlook
-
Momenta Phama (MNTA) Announces Young Kwon, Ph.D. as CFO
-
Momenta Phama (MNTA) CFO Michelle Robertson Resigns
-
Momenta Phama (MNTA) Announces Dr. Jane F. Barlow to Board
-
Momenta Phama (MNTA) Prices 14.516M Share Common Offering at $15.50/Sh
-
Pre-Open Movers 12/11: (PTI) (OLLI) (PLAB) Higher (ITRM) (GME) (PLCE) Lower (more...)
Back to MNTA Stock Lookup